AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6756931
Drug: Terbutaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline infusion during acebutolol medication
Trial: 3883878
Drug: Acebutolol 400
RxNorm normalized name: acebutolol 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol 400 mg
Trial: 11899174
Drug: Cold crystalloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold crystalloid perfusion (4 degrees C Ringer's lactate solution)
Trial: 9645457
Drug: Granisetron (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (0.5 mg i.v. bolus + continuous infusion of 0.04 mg/h for 7 days)
Trial: 8174846
Drug: Vehicle (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (50 ml saline)
Trial: 3237194
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion (3,680 mIU in 45 min)
Trial: 23713245
Drug: Aspirin (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (Group B)
Trial: 19114685
Drug: Control (bevacizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (bevacizumab and chemotherapy without panitumumab)
Trial: 3300174
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion therapy (CSII)
Trial: 29607554
Drug: Hydrocortisone butyrate
RxNorm normalized name: Hydrocortisone Butyrate
DrugBank: Hydrocortisone butyrate (DB14540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone butyrate ointment
Trial: 15643131
Drug: Candesartan 8
RxNorm normalized name: candesartan 8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 8 mg daily for 16 weeks
Trial: 15643131
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg daily for 16 weeks
Trial: 11881123
Drug: Candesartan 16
RxNorm normalized name: candesartan 16 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 16 mg once-daily
Trial: 7824108
Drug: 20% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% glucose infusion
Trial: 8173308
Drug: 150% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150% of calculated daily calorie intake
Trial: 26067435
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment mismatching the biomarker indication
Trial: 12885805
Drug: Subcutaneous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous low-dose IFNalpha2b (3 million international units [MU]/m2/d, days 1 to 7, week 1; three times weekly, weeks 3 to 6, repeated all 6 weeks) plus IL-2 (9 MU/m2/d, days 1 to 4, week 2 of each cycle) for 48 weeks
Trial: 12885805
Drug: Subcutaneous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous low-dose IFNalpha2b plus IL-2
Trial: 1664869
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride (NaCl; placebo), dosage: 1.5 g total, 2.5 h prior to exercise
Trial: 7208632
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of active head rotation toward the extending wrist and vibration of the extensor surface
Trial: 26652904
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogens (oCEE)
Trial: 18587579
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion etoposide
Trial: 12458394
Drug: Insulin-stimulated myocardial
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-stimulated myocardial glucose uptake.
Trial: 10362195
Drug: Carvedilol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (mean dosage 74±23 mg/day)
Trial: 10362195
Drug: Metoprolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (mean dosage 142±44 mg/day)
Trial: 7557850
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) alfa therapy
Trial: 31136431
Drug: New oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New oral anticoagulants
Trial: 24315724
Drug: New oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New oral anticoagulants (low-dose)
Trial: 16263866
Drug: PTSD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTSD treatment for peacekeepers
Trial: 16263866
Drug: PTSD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTSD treatment for Vietnam veterans
Trial: 12198002
Drug: Iron bis-glycine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron bis-glycine chelate (encapsulated in enteric gelatin capsules)
Trial: 30959472
Drug: Standard-of-care treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care treatment (control)
Trial: 27105563
Drug: 2-dose adult
RxNorm normalized name: glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose adult formulation
Trial: 27105563
Drug: 3-dose paediatric
RxNorm normalized name: glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose paediatric formulation
Trial: 27105563
Drug: Challenge dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Challenge dose of monovalent vaccine
Trial: 10763172
Drug: Xylometazoline-Dexpanthenol nasal
RxNorm normalized name: xylometazoline Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylometazoline-Dexpanthenol nasal spray
Trial: 10763172
Drug: Xylometazoline nasal
RxNorm normalized name: xylometazoline nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylometazoline nasal spray
Trial: 24596456
Drug: Tobramycin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin (80 mg/2 mL)
Trial: 9886454
Drug: 1 microg
RxNorm normalized name: Alpha 1 microglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microg 1alpha(OH)D3 daily (treatment group, n=43)
Trial: 9886454
Drug: 1 microg
RxNorm normalized name: Alpha 1 microglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microg 1alpha(OH)D3 daily (treatment group)
Trial: 10978944
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg loperamide
Trial: 19159021
Drug: Tetracycline solution
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline solution (100 mg/mL) applied with a microbrush plus scaling and root planing (SRP+T)
Trial: 19159021
Drug: Tetracycline solution
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline solution (100 mg/mL) applied with a microbrush (T)
Trial: 16895678
Drug: Lifestyle measures
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle measures and pharmacological treatment of metabolic disorders
Trial: 10982198
Drug: Sertraline (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50-100 mg)
Trial: 9447852
Drug: BIS combined
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS combined with treatment history
Trial: 2228324
Drug: Theophylline ethylenediamine
RxNorm normalized name: Theophylline ethylenediamine
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline ethylenediamine (2.5 mg/kg)
Trial: 2228324
Drug: Theophylline ethylenediamine
RxNorm normalized name: Theophylline ethylenediamine
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline ethylenediamine (5.0 mg/kg)
Trial: 2228324
Drug: Theophylline ethylenediamine
RxNorm normalized name: Theophylline ethylenediamine
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline ethylenediamine (7.5 mg/kg)
Trial: 28044255
Drug: Mavoglurant (modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavoglurant (modified release) as augmentation therapy to SSRIs
Trial: 26203098
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg oral iodine daily for 6 months
Trial: 18972723
Drug: Elongated needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elongated needle therapy
Trial: 14669965
Drug: PUFA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUFA supplementation (480 mg DHA, 80 mg EPA, 40 mg AA, 96 mg GLA, 24 mg alpha‐tocopheryl acetate)
Trial: 8874562
Drug: Warmed intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warmed intravenous fluids
Trial: 30229439
Drug: Propranolol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (2 mg/kg/day) administered during the neovascularization phase of ROP (stage 2)
Trial: 30229439
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline solution (control group)
Trial: 24309401
Drug: Metoprolol 50
RxNorm normalized name: metoprolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 50 mg once daily for 15 days
Trial: 24309401
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no β‐blocker therapy)
Trial: 20509074
Drug: Temporal sequence
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporal sequence of suggestions (L followed by M)
Trial: 12032037
Drug: Continuous psoas
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous psoas compartment block (CPCB) with 0.2% ropivacaine, initial loading dose of 0.4 mL/kg, followed by continuous infusion for 48 hours.
Trial: 10221186
Drug: 1% preservative-free
RxNorm normalized name: lidocaine 1% preservative-free injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% preservative-free lidocaine intracameral injection
Trial: 429218
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion with papaverin and dextran
Trial: 27686182
Drug: Tdap vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap vaccine (0.5 mL IM)
Trial: 12201616
Drug: Oxybutynin ER
RxNorm normalized name: Oxybutynin Chloride 5 MG Oral Tablet, Extended Release [OXYBUTYNIN ER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin ER 5 mg
Trial: 12201616
Drug: Oxybutynin ER
RxNorm normalized name: Oxybutynin Chloride 5 MG Oral Tablet, Extended Release [OXYBUTYNIN ER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin ER 10 mg
Trial: 479006
Drug: Indomethacin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (25 mg three times a day for three days preoperatively and three weeks postoperatively)
Trial: 31156083
Drug: Extended course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended course (EC) prednisolone therapy: 60 mg/m2/day for weeks 1-4, tapering from 60 mg/m2 on alternate days for weeks 5-16 (total 3150 mg/m2)
Trial: 31156083
Drug: Standard course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard course (SC) prednisolone therapy: 60 mg/m2/day for weeks 1-4, 40 mg/m2 on alternate days for weeks 5-8, and matching placebo for weeks 9-18 (total 2240 mg/m2)
Trial: 31156083
Drug: Extended course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended course (EC) prednisolone therapy
Trial: 29936923
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (200 μg/d as Se yeast)
Trial: 25346332
Drug: Cold Infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold Infusions (CI) at 4°C, 2L at 4L/h
Trial: 25346332
Drug: Cold Infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold Infusions (CI)
Trial: 15705374
Drug: Oral L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-carnitine (2 g/day) for 3 months
Trial: 12431966
Drug: TNP-470 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNP-470 at 60 mg/m² three times per week and paclitaxel at 225 mg/m² administered over 3 hours every 3 weeks
Trial: 16454441
Drug: Pravastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (20 mg/d)
Trial: 2206826
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg) and nifedipine retard (20 mg) once daily
Trial: 12182261
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg once daily)
Trial: 2206826
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of atenolol and nifedipine
Trial: 113074
Drug: 2000 rad
RxNorm normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 rad in 8 fractions over 10 days with intravenous 5 Fluorouracil (5 F.U.) at a dose of 500 mg daily x 4 days preirradiation and then 12.5 mg/kg daily for 5 days every 28 days for six courses.
Trial: 16892265
Drug: Red mixed
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red mixed berry juice (700 mL daily, TEAC: 19.1 mmol/L trolox)
Trial: 16892265
Drug: Control juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control juice (polyphenol-depleted, TEAC: 2.4 mmol/L trolox)
Trial: 9378844
Drug: YM90K (36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YM90K (36 mg single dose, 24 mg repeated dose over 3 hours)
Trial: 9378844
Drug: YM90K (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YM90K (24 mg repeated doses)
Trial: 28931500
Drug: Web-based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based Cognitive Remediation Therapy (CogRem)
Trial: 25742919
Drug: Tirasemtiv 250
RxNorm normalized name: Tirasemtiv
DrugBank: Tirasemtiv (DB12209)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirasemtiv 250 mg
Trial: 11518200
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (25 g/d providing 7.5 g n-3 LCPUFAs)
Trial: 11518200
Drug: High-oleic sunflower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-oleic sunflower oil (25 g/d providing 22 g monounsaturated fatty acids)
Trial: 9545673
Drug: Cefopzopran (CZOP)
RxNorm normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefopzopran (CZOP) 18.75 mg/kg
Trial: 3731682
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg po q.i.d. for 2 weeks)
Trial: 27652679
Drug: Paracetamol (taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (taken regularly or as needed)
Trial: 24917631
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus osteopathic manipulative treatment (SC+OMT)
Trial: 18445141
Drug: AGN 201904‐Z
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN 201904‐Z (600 mg/day)
Trial: 18445141
Drug: Esomeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (40 mg/day)
Trial: 11576031
Drug: QI-medications program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QI-medications program
Trial: 11576031
Drug: QI-therapy program
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QI-therapy program
Trial: 3581030
Drug: CHOP without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHOP without intermediate dose methotrexate
Trial: 12823235
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (30 micro g/ml zinc)
Trial: 11728289
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 32 mg (with hydrochlorothiazide 12.5 mg if DBP was 90 mmHg or higher at week 8)
Trial: 8840098
Drug: aprotinin (200,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aprotinin (200,000 U.I.C. as intravenous bolus injection)
Trial: 8840098
Drug: placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (10 ml isotonic saline)
Trial: 1538302
Drug: Cimetidine 5
RxNorm normalized name: IBUPROFEN 2 g in 100 g / CIMETIDINE 5 g in 100 g / SALICYLIC ACID 17 g in 100 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 5 mg/kg
Trial: 1538302
Drug: Cimetidine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 7.5 mg/kg
Trial: 30753623
Drug: L-histidine injection
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-histidine injection
Trial: 29193943
Drug: Local steroids
RxNorm normalized name: RECTAL,LOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local steroids combined with therapeutic exercise at home
Trial: 29193943
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy (Control)
Trial: 26427112
Drug: Standard DCXC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard DCXC therapy (2-g corbrin capsules, 3 times/d, 3 days before and after angiography)
Trial: 26427112
Drug: Intensive DCXC
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive DCXC therapy (3-g corbrin capsules, 3 times/d, 3 days before and after angiography)
Trial: 15742419
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment group
Trial: 26427112
Drug: Standard DCXC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard DCXC therapy
Trial: 26427112
Drug: Intensive DCXC
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive DCXC therapy
Trial: 23123272
Drug: Carbohydrate-electrolyte solution
RxNorm normalized name: CARBOHYDRATE/ELECTROLYTES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-electrolyte solution (CES)
Trial: 9472784
Drug: GR213487B liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR213487B liquid nasal spray (0.4375mg, 4.0mg, or 0.0625mg)
Trial: 8543620
Drug: Flow cytometry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flow cytometry analysis leading to anti-D immunoglobulin administration
Trial: 23086971
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 tablet twice daily)
Trial: 30635033
Drug: Clazakizumab (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazakizumab (subcutaneous administration of 25 mg in monthly intervals)
Trial: 8359292
Drug: Low-dose acetylsalicylic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acetylsalicylic acid (ASA, 75 mg daily)
Trial: 27247434
Drug: COBRA-light therapy
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COBRA-light therapy (prednisolone 30 mg/day, tapered to 7.5 mg/day in 8 weeks and MTX)
Trial: 21134017
Drug: Caffeinated alcoholic
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeinated alcoholic beverage (69 mg caffeine/12 oz beer)
Trial: 1487551
Drug: Verapamil (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (120 mg three times daily for 3 days)
Trial: 1487551
Drug: Acute volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute volume expansion (1500 mL saline in 15 minutes, in supine legs-up position)
Trial: 3021488
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (4 mg) q.i.d.
Trial: 3021488
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (4 mg) b.i.d.
Trial: 28315450
Drug: Carotenoid supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotenoid supplementation (Macushield™: 10 mg meso-zeaxanthin, 10 mg lutein, 2 mg zeaxanthin)
Trial: 25824243
Drug: rhGH (47.6-52.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (47.6-52.4 μg/kg/day) and low-dose stanozolol (20-35 μg/kg/day)
Trial: 24317497
Drug: Web-based psychoeducational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based psychoeducational program (Diapason), 12 weeks duration, weekly sessions
Trial: 19484836
Drug: Vascular care
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vascular care (treatment according to strict guidelines for hypercholesterolemia and hypertension, including acetylsalicylic acid, folic acid, and pyridoxine)
Trial: 9640158
Drug: Thiopental 5
RxNorm normalized name: thiopental 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental 5 mg kg‐1 (AT‐R group)